Minute Insight: Abbott Is Planning To Combine Glucose And Ketone Measurement Into One Wearable
The company announced that it is developing a new biowearable device that will continuously monitor both glucose and ketone levels with one sensor.
You may also be interested in...
In this month’s Digital Health roundup, Medtech Insight’s Marion Webb discusses her deep-dive article on menopause with leading experts in this rising industry and Barnaby Pickering highlights UK-based Proximie, which developed a web-based platform that allows surgeons and other clinical experts to collaborate virtually in the operating suite. The company recently raised $80m in a series C round.
Korean pharma firm poised to file for domestic approval of SGLT-2 inhibitor enavogliflozin after positive top-line Phase III data, marking progress for the country's first drug in the already crowded class. But will it be competitive?
Abbott announced at CES 2022 it is developing a line of consumer wearables, starting with a device to track ketones continuously, which is expected to launch in Europe this year.